20n Bio
PrivateLast Round
Seed
May 20, 2026
Total Funding Raised
$10.8M
Company Overview
20n Bio is a biotechnology company that utilizes an AI-powered high-throughput screening platform to discover and develop novel cyclic peptide therapeutics for oncology and other genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
20n Bio Comparables
Compare 20n Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Menten AI | 83% | |
| Dayra Therapeutics | 82% | |
| AbbVie | 82% | |
20n Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 20, 2026 | ||||
| Seed | Dec 17, 2021 |
20n Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Seed |
| Lanchi Ventures | Seed |
20n Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about 20n Bio's valuation, stock price, and market status.